Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various unive... Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology. Show more
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the โCompanyโ) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the โCompanyโ) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the โCompanyโ) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273...
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the โCompanyโ) (Euronext Growth: ALCLS - NASDAQ:ย CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.03 | -1.34529147982 | 2.23 | 2.4 | 2.16 | 11385 | 2.29734814 | CS |
4 | -0.2 | -8.33333333333 | 2.4 | 2.425 | 2.16 | 17969 | 2.32388386 | CS |
12 | 0.33 | 17.6470588235 | 1.87 | 2.43 | 1.84 | 42514 | 2.16328313 | CS |
26 | -0.18 | -7.56302521008 | 2.38 | 3.38 | 1.82 | 49140 | 2.45911052 | CS |
52 | 0.51 | 30.1775147929 | 1.69 | 3.7735 | 0.962777 | 518854 | 2.71360703 | CS |
156 | -11.65 | -84.1155234657 | 13.85 | 13.93 | 0.962777 | 269169 | 3.53127468 | CS |
260 | -9.21 | -80.7186678352 | 11.41 | 34.71 | 0.962777 | 249990 | 9.29939329 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.